Trials / Unknown
UnknownNCT04356508
COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Dr Gerry Gin Wai Kwok · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, controlled, single-centre pilot study of nivolumab in adult patients with COVID-19. This clinical study aims to evaluate efficacy of anti-PD1 antibody in relation to viral clearance and its safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Single dose at 0.3mg/kg |
Timeline
- Start date
- 2020-04-14
- Primary completion
- 2020-06-30
- Completion
- 2021-08-31
- First posted
- 2020-04-22
- Last updated
- 2020-04-22
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04356508. Inclusion in this directory is not an endorsement.